Citation Impact
Citing Papers
Directed evolution of the tryptophan synthase β-subunit for stand-alone function recapitulates allosteric activation
2015 StandoutNobel
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
2011
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
2004
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
2015
Plant Cuticular Lipid Export Requires an ABC Transporter
2004 StandoutScience
Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides
2019 StandoutNobel
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
2002
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
1998
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
2006
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
2001
Cancer Statistics, 2021
2021 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
ErbB-targeted therapeutic approaches in human cancer
2003
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
2017
A view on drug resistance in cancer
2019 StandoutNature
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Biosynthesis and secretion of plant cuticular wax
2002
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
2009 StandoutNature
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
2015
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism
2002 Standout
Imaging in the era of molecular oncology
2008 StandoutNature
Lung Cancer
2008 Standout
The MET axis as a therapeutic target
2009
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
2008
Extensive Crosstalk between O-GlcNAcylation and Phosphorylation Regulates Akt Signaling
2012
Protein‐Reactive Natural Products
2005
ErbBs in lung cancer
2008
Cancer driver mutations in protein kinase genes
2008
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
2009
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Emerging Biological Principles of Metastasis
2017 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
AKT/PKB Signaling: Navigating the Network
2017 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Acquired resistance to TKIs in solid tumours: learning from lung cancer
2014
Dynamics and diversity in autophagy mechanisms: lessons from yeast
2009 StandoutNobel
Lectin Domains of Polypeptide GalNAc Transferases Exhibit Glycopeptide Binding Specificity
2011 StandoutNobel
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Crystal structures of the sugar complexes of Streptomyces olivaceoviridis E-86 xylanase: sugar binding structure of the family 13 carbohydrate binding module
2002
Crystal structure of Streptomyces olivaceoviridis E-86 β-xylanase containing xylan-binding domain
2000
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
2017 Standout
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Iron Catalysis in Organic Synthesis
2015 Standout
BindingDB Entry 50022499: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
2025
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Substrate-binding domains of glycanases from Streptomyces lividans: characterization of a new family of xylan-binding domains
1998
Targeted Covalent Inhibitors for Drug Design
2016
Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications
2019 Standout
Selective Differentiation of Neural Progenitor Cells by High-Epitope Density Nanofibers
2004 StandoutScience
Chem-Bioinformatics and QSAR: A Review of QSAR Lacking Positive Hydrophobic Terms
2001 Standout
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
2006 StandoutNature
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
SKI-606, a Src/Abl Inhibitor withIn vivoActivity in Colon Tumor Xenograft Models
2005
Ribosomal Synthesis of Dehydroalanine-Containing Peptides
2006 StandoutNobel
Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6
2014
Cancer Genome Landscapes
2013 StandoutScience
Chemistry of Biologically Important Synthetic Organoselenium Compounds
2001 Standout
Synthesis of Quinazolin-4(3H)-ones via Amidine N-Arylation
2013
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
2009
A Heck–Matsuda Process for the Synthesis of β‐Arylethenesulfonyl Fluorides: Selectively Addressable Bis‐electrophiles for SuFEx Click Chemistry
2016 StandoutNobel
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
2009
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
Fluorine in medicinal chemistry: A review of anti-cancer agents
2006
Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia
2002
Mechanism by which the lectin actinohivin blocks HIV infection of target cells
2009 StandoutNobel
Two tail-anchored protein variants, differing in transmembrane domain length and intracellular sorting, interact differently with lipids
2005
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
2016 StandoutNobel
Noncovalent Cell Surface Engineering: Incorporation of Bioactive Synthetic Glycopolymers into Cellular Membranes
2008 StandoutNobel
An Arabidopsis Homolog of YeastATG6/VPS30Is Essential for Pollen Germination
2007 StandoutNobel
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Developmental changes in neural progenitor cell lineage commitment do not depend on epidermal growth factor receptor signaling
2000
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Works of Patrick W. Vincent being referenced
A Sec14p-nodulin domain phosphatidylinositol transfer protein polarizes membrane growth of Arabidopsis thaliana root hairs
2005
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
2007
Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions
2000
Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by18F-FDG Small-Animal PET
2007
Synthesis and structure based optimization of novel Akt inhibitors
2008
Lipid trafficking in plant cells
1998
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma
2006
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts
2000
Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions.
2000
Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor
1999
Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor
1997
Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor
2000
ATP-Dependent Formation of Phosphatidylserine-Rich Vesicles from the Endoplasmic Reticulum of Leek Cells
1999
Soluble 2-Substituted Aminopyrido[2,3-d]pyrimidin-7-yl Ureas. Structure−Activity Relationships against Selected Tyrosine Kinases and Exploration of in Vitro and in Vivo Anticancer Activity
2001
Tyrosine Kinase Inhibitors. 14. Structure−Activity Relationships for Methyl- amino-Substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)- pyrido[3,4-d]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Factors
1998
Tyrosine Kinase Inhibitors. 6. Structure−Activity Relationships among N- and 3-Substituted 2,2‘-Diselenobis(1H-indoles) for Inhibition of Protein Tyrosine Kinases and Comparative in Vitro and in Vivo Studies against Selected Sulfur Congeners
1997
New α-l -arabinofuranosidase produced by Streptomyces lividans: cloning and DNA sequence of the abfB gene and characterization of the enzyme
1997